The WAIT Trial: Waiting Versus Active Induction at Term in Women With A1 Gestational Diabetes Mellitus
A legfontosabb adatok
- Ki végzi
- Peking University Third Hospital
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 1500 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Timing of Planned Delivery
- A regiszteradat frissítve
- 2026. október 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for women pregnant with their first baby who have diet-controlled gestational diabetes (A1 GDM) and plan a vaginal birth. It compares starting labor at 40 weeks with waiting until 41 weeks.
- Életkor
- 18 to 40 years
- Nem
- Women only
- A betegség stádiuma
- Pregnancy with one baby, first birth. Gestational diabetes found by an oral glucose tolerance test (OGTT) at 24-28 weeks. Blood sugar must be on target with diet and exercise only (A1 GDM).
- Korábbi kezelés
- No insulin or other glucose-lowering medicines during this pregnancy.
- Biomarker vagy leletérték
- Gestational diabetes diagnosed by oral glucose tolerance test (OGTT).
A részvétel fő kizáró okai
- Labor already started, or waters broken before labor
- Past cesarean or womb surgery through the muscle wall, or a planned cesarean
- Serious pregnancy problems such as high blood pressure in pregnancy, liver cholestasis, severe heart disease or severe anemia
- Baby not head-down, baby too small or too large, birth defects, or too little or too much amniotic fluid
- Placenta problems (such as placenta previa), or cannot have misoprostol or oxytocin (for example asthma, glaucoma, allergy)
Ez a vizsgálat csak várandós résztvevőket keres. A regiszter mondata, amelyen ez alapul: * Singleton pregnancy;
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Aged 18-40 years
- Singleton pregnancy
- Nulliparous
- Diagnosed with gestational diabetes mellitus (GDM) by oral glucose tolerance test (OGTT) at 24-28 weeks of gestation
- At screening/enrollment, classified as A1 GDM, defined as good glycemic control after exercise counseling and nutritional management. Both of the following criteria must be met: (1) No use of insulin or other glucose-lowering medications during pregnancy up to screening/enrollment, verified through medication orders in the hospital information system (HIS); and (2) The clinician assesses overall glycemic control during pregnancy as meeting target and A1 GDM can be clearly identified through medical record information
- Provides written informed consent
Ki nem vehet részt
- Maternal factors: signs of labor (regular progressive uterine contractions accompanied by progressive cervical effacement, cervical dilation and fetal descent); prelabor rupture of membranes; history of cesarean delivery or uterine surgery penetrating the myometrium (e.g., myomectomy; hysteroscopy, induced-abortion and other non-myometrial-penetrating surgeries are excluded); clinically assessed pelvic contraction; cervical cerclage during the current pregnancy; planned cesarean delivery or any known contraindication to vaginal delivery; or severe pregnancy-related complications or comorbidities considered by the investigator to preclude tolerance of vaginal delivery, such as severe heart disease complicating pregnancy, intrahepatic cholestasis of pregnancy, hypertensive disorders of pregnancy, psychiatric disorders/cognitive impairment, autoimmune diseases, or severe anemia
- Placental factors: placenta previa, vasa previa, placenta accreta spectrum, or similar conditions
- Medication-related contraindications: contraindications to cervical ripening or labor-inducing agents including misoprostol and oxytocin, such as asthma, glaucoma, scarred uterus, or hypersensitivity to above-mentioned drugs
- Fetal factors: non-cephalic presentation; intrauterine fetal demise; fetal distress; fetal structural malformations, chromosomal abnormalities, or other related anomalies; fetal growth restriction (pathologically driven failure of the fetus to reach its genetically-determined growth potential due to maternal, fetal or placental disorders, most commonly manifested as ultrasound-estimated fetal weight or abdominal circumference below the 10th percentile for corresponding gestational age); or large-for-gestational-age fetus (ultrasound-estimated fetal weight above the 90th percentile for corresponding gestational age)
- Amniotic fluid factors: oligohydramnios, defined as an amniotic fluid index (AFI) ≤5 cm or a deepest vertical pocket (DVP) ≤2 cm; or polyhydramnios, defined as an AFI ≥25 cm or a DVP ≥8 cm
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 40 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This multicenter, open-label, superiority randomized controlled trial will evaluate whether delaying planned induction from 40 weeks to 41 weeks improves delivery outcomes in women with A1 gestational diabetes mellitus (A1 GDM). The study is designed to enroll 1,500 eligible women (750 per group), all of whom are planned for vaginal delivery.
A teljes eredeti leírásKevesebb
Eligible participants are women aged 18-40 years with singleton pregnancy and who are primiparous. GDM will be diagnosed using OGTT at 24-28 weeks, and participants must meet criteria for A1 GDM, meaning blood glucose is controlled with diet and exercise only (no insulin or other glucose-lowering medications during pregnancy). After providing written informed consent, participants will be randomized 1:1 to one of two pre-specified induction strategies.
Control group (planned induction at 40 weeks): Participants will have planned induction at 40+0 weeks (time window 39+6 to 40+0). If spontaneous labor occurs before or during the window, obstetric management will follow routine clinical practice. If labor has not started by the end of the window, induction will be performed according to the protocol.
Intervention group (expectant management until 41 weeks): Participants will be managed expectantly until 41+0 weeks with planned induction in the 41+0 to 41+1 weeks window. If spontaneous labor occurs before or during the window, routine obstetric management will be used. If labor has not started by the end of the window, induction will be performed according to the protocol.
Participants will be followed from randomization until delivery and hospital discharge, with selected outcomes followed up to postpartum day 42. The primary outcome is the cesarean delivery rate. Secondary outcomes include maternal outcomes such as postpartum hemorrhage and other obstetric complications, neonatal/perinatal outcomes including perinatal death, and need for respiratory support, as well as selected health-economic and patient-reported outcomes. All participating centers will apply standardized procedures for screening, monitoring, induction methods, and data collection. An independent Data and Safety Monitoring Board (DSMB) and a blinded Clinical Endpoint Committee will monitor safety and validate the primary outcome.
The trial is expected to be completed within approximately 18 months after initiation of recruitment, and the results will provide high-quality evidence to inform timing of delivery for women with A1 GDM in China.
A vizsgálat 2 csoportja
- Experimental ArmA vizsgált kezelés
Pregnant women in this arm will receive expectant management until 41+0 weeks (time window: 41+0-41+1 weeks). Routine obstetric care will be provided if spontaneous labor occurs. Labor induction will be conducted for those without spontaneous labor.
Kezelés: Timing of Planned Delivery
- Control ArmMár használt kezelés, összehasonlításként
Pregnant women in this arm will receive planned labor induction at 40+0 weeks (time window: 39+6-40+0 weeks). Routine obstetric care will be provided if spontaneous labor occurs. Labor induction will be conducted for those without spontaneous labor.
Kezelés: Timing of Planned Delivery
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Induction of Labor at 40 Weeks Versus Expectant Management Until 41 Weeks in Women With A1 Gestational Diabetes Mellitus: A Multicenter, Open-Label, Superiority Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Illeszkedési kérdések
- Forrás: NCT07831954: ki vehet részt
- A regiszteradat frissítve
- 2026. október 22.